We have demonstrated and validated a core panel of five protein biomarkers that differentiates between newly diagnosed PCa and healthy controls, highlighting the utility of such biomarker signatures and potentially complementing PSA as a diagnostic tool. The gene discussed is KLK3; the disease is posterior cortical atrophy.